NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report) – Equities researchers at Zacks Small Cap decreased their FY2024 earnings per share (EPS) estimates for shares of NeuroBo Pharmaceuticals in a report released on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz now anticipates that the company will post earnings per share of ($3.83) for the year, down from their previous estimate of ($2.83). The consensus estimate for NeuroBo Pharmaceuticals’ current full-year earnings is ($3.00) per share. Zacks Small Cap also issued estimates for NeuroBo Pharmaceuticals’ FY2025 earnings at ($2.59) EPS.
NeuroBo Pharmaceuticals Trading Up 1.3 %
Shares of NASDAQ:NRBO opened at $3.10 on Friday. The company has a 50-day moving average price of $4.43 and a two-hundred day moving average price of $3.96. NeuroBo Pharmaceuticals has a twelve month low of $2.89 and a twelve month high of $6.75.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
Featured Articles
- Five stocks we like better than NeuroBo Pharmaceuticals
- How to Calculate Inflation Rate
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Calculate Options Profits
- How to Use Put Debit Spreads to Profit From Falling Stocks
- NYSE Stocks Give Investors a Variety of Quality Options
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
